September's highlights
September has seen #ESMO2024, prostate cancer awareness month, and many new advances, collaborations, and contributions to the world of oncology and biopharmaceuticals.
Here's a recap of the key highlights and insights from this past month:
?? AI’s Role in Cancer Diagnosis at ESMO 2024
?? Prior to ESMO 2024, Dr. Oscar Juan-Vidal, MD, PhD, shared his perspectives on the role of AI in cancer diagnostics.
Dr. Juan-Vidal, who is a thoracic medical oncologist, highlighted how AI is not only improving diagnostic accuracy but also enabling earlier detection of lung cancer through advanced imaging analysis.
He also discussed the future role of AI in personalizing cancer treatments, integrating genomic data, and enhancing decision-making in clinical practice. These discussions emphasized that AI is moving from theory to practice, driving improvements in patient outcomes by integrating complex data in real-time.
Prostate Cancer Awareness Month
?? September marked #ProstateCancerAwarenessMonth, an important opportunity to address the ongoing challenges in prostate cancer detection:
As this infographic highlights, accuracy in diagnosis is key. As a solution to that, Quibim’s QP-Prostate? is the only tool trained with both systematic and targeted biopsies that improves diagnostic sensitivity from 79.8% to 90.4%.
领英推荐
Partnership with Macor in Argentina
???????? In September, we formalized our partnership with Macor , a leading company in the Argentinian healthcare sector, to support our expansion into Latin America. The collaboration aims to enhance diagnostic capabilities in Argentina by leveraging Macor’s local expertise and Quibim’s AI-driven imaging solutions.
Radiomics: Understanding the future of medical imaging
?? In response to a previous survey we launched for all of you, we released an informative carousel about what radiomics is.
Radiomics, the extraction of large amounts of quantitative features from medical images, is transforming how we analyze imaging data and identify biomarkers, as it predicts disease characteristics and patient outcomes, improving diagnosis and treatment personalization.
Enhancing drug development with QP-Insights?
??The road to bringing a new drug to market is fraught with challenges—high costs, long timelines, and the risk of failure due to poor patient selection.
As a response to this, Quibim’s QP-Insights? platform offers a solution by using AI and radiomics to improve patient selection, enable non-invasive monitoring, and provide comprehensive biomarker data.
Click on the image below to download our infographic on Radiomics Pipeline:
?? If you would like to receive first-hand information from us, don't forget to subscribe to our email newsletter here!
#AIinHealthcare #MedicalImaging #ProstateCancer #Radiomics #ESMO2024 #HealthcareInnovation